CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D007246: Infertility NIH

(Synonyms: Infert, Infertil, Infertili, Infertility)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)


Name (Synonyms) Correlation
drug897 Exposure: Covid-19 infection Wiki 0.45
drug996 Generalized Anxiety Disorder-7 (GAD-7) Wiki 0.45
drug1770 Patient Health Questionnaire-9 (PHQ-9) Wiki 0.45
drug1978 Questionnaire Wiki 0.19
drug377 Blood sample Wiki 0.15

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D007247 Infertility, Female NIH 0.45
D007248 Infertility, Male NIH 0.45

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0000789 Infertility HPO 1.00
HP:0003251 Male infertility HPO 0.45
HP:0008222 Female infertility HPO 0.45

There are 5 clinical trials

Clinical Trials


1 Impact of COVID-19 Pandemic on the Psychological Status of Infertile Patients Who Had in Vitro Fertilization Treatment Interrupted or Postponed

Infertility is a severely distressing experience for many couples. Depression and anxiety are psychological disorders associated with infertility, and they may worsen during infertility treatments. This study times to understand the changes in the psychological status of infertile patients who had in vitro fertilization (IVF) treatment interrupted or postponed because of the COVID-19 pandemic.

NCT04395755 Infertility, Female ART IVF COVID-19 Behavioral: Generalized Anxiety Disorder-7 (GAD-7) Behavioral: Patient Health Questionnaire-9 (PHQ-9)
MeSH:Infertility Infertility, Female
HPO:Female infertility Infertility

Primary Outcomes

Measure: Severity of anxiety

Time: 1-4 weeks after communication of interrupted or delayed IVF

Measure: Severity of depression

Time: 1-4 weeks after communication of interrupted or delayed IVF

2 Patients Perspectives on Discontinuation of Their Fertility Treatment Due to the COVID-19 Pandemic

The COVID-19 pandemic brought new challenges to our nationwide healthcare system, with rapid escalation of the number of affected individuals over a handful of weeks. From March 13, a first set of measures was taken to minimise the spread of the virus, which largely impacted societal and economical daily life. A view days later, on March 17, the country was put in "lockdown" and all non-urgent medical treatments were cancelled or postponed. As recommended by the major scientific fertility societies, all non-ivf fertility treatments were discontinued abruptly, whereas started ivf stimulations were continued until oocyte aspiration, where after a freeze-all strategy was applied. There is little information available for women aiming for pregnancy or embarking on assisted conception. Given the modelling of the pandemic, including the time to peak and subsequent tail, considerable delays in conception to substantially attenuate risk may be required, which will inevitably impact patients wellbeing and overall success rates. A questionnaire was developed to explore patients perspectives on different aspects of their fertility treatment during the COVID-19 pandemic. The questionnaire contains the following sections: - demographic variables; - questions regarding the fertility history of the respondent; - questions regarding the impact of fertility treatment cancellation / postponing fertility treatment during COVID-19 on their life, psychological wellbeing and relationship; - questions regarding continuing medical treatment on their own, or seeking treatment elsewhere; - questions regarding the satisfaction of measures taken by their fertility center regarding the COVID-19 pandemic; - questions regarding expectations of further treatments, with focus on safety issues related to the COVID-19 pandemic. Eligible patients will be selected electronically from our database and digital agenda. After selection, patients will be contacted via email to participate. Two reminders will be send in case the questionnaire is not filled out: a first reminder after one week, a second reminder after two weeks.

NCT04396210 Coronavirus COVID ART Fertility Issues Other: Questionnaire
MeSH:Infertility
HPO:Infertility

Primary Outcomes

Measure: Patients perspectives on the abruptly discontinuation of their fertility treatment by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

Measure: Patients reproductive behaviour by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

Measure: Patients views on resuming fertility treatment by using a questionnaire

Time: During the COVID-19 pandemic, from March 2020 till June 2020

3 Determining the Reproductive Health of Men Post-COVID-19 Infection

Study rationale 1. An increasing proportion of the worldwide population is being infected with COVID-19. 2. There are ongoing and currently unanswered safety concerns about the effects of COVID-19 on reproductive health. 3. It will be immensely reassuring to rapidly report that COVID-19 has no detectable effects on male endocrine or sperm function. Conversely, if COVID-19 does impair male reproductive health, appropriate screening can be performed in couples trying to conceive, and further research can be undertaken. 4. The proposed study will be simple, rapid, and authoritative for the UK and worldwide.

NCT04414904 Infertility, Male Testosterone Deficiency Other: Exposure: Covid-19 infection
MeSH:Infertility Infertility, Male
HPO:Infertility Male infertility

Primary Outcomes

Description: Sperm concentration (x10^6/ml) between case and control group.

Measure: Semen parameters

Time: 3 visits (up to 75 days apart)

Description: Sperm Motility (%) between case and control group.

Measure: Sperm Parameters

Time: 3 visits (up to 75 days apart)

Description: Sperm normal morphology (%) between case and control group.

Measure: Sperm Parameters

Time: 3 visits (up to 75 days apart)

Description: Testosterone (nmol/L) between case and control group.

Measure: Hormones measurement

Time: 3 visits (up to 75 days apart)

Description: Follicle Stimulating Hormone(IU/L) between case and control group.

Measure: Hormones measurement

Time: 3 visits (up to 75 days apart)

Description: Luteinising hormone(IU/L) between case and control group.

Measure: Hormones measurement

Time: 3 visits (up to 75 days apart)

Secondary Outcomes

Description: Compare seminal reactive oxidative species (RLU/second/10^6sperm) between case and control group.

Measure: Seminal Reactive oxygen species

Time: 3 visits (up to 75 days apart)

Description: Compare Sperm DNA fragmentation rate (%) between case and control group.

Measure: Sperm DNA fragmentation rate

Time: 3 visits (up to 75 days apart)

4 Detection of SARS-CoV-2 in Follicular Fluid and Cumu-lus-oocyte-complexes From COVID-19 Patients During Controlled Ovarian Stimulation for ICSI Treatment

Recently, the world was shaken awake by a pandemic caused by a novel coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). In most nations drastic isolation measures were taken to minimize the further spread of the Coronavirus Disease 2019 (COVID-19). Being the first pandemic sparked by a Coronavirus, little was known on COVID-19 and its implications on general health. Our understanding on the virus and its potential effects on health is growing. In Belgium, the situation is stabilizing, and doctors and healthcare workers are slowly recommencing routine work and consultations. As also fertility treatments were abruptly interrupted, many patients are in need to resume their treatment. The limited evidence of SARS-CoV-2 on pregnancy seems to be rather satisfying1, but practically nothing is known about the possible impact of an active SARS-CoV-2 infection on female gametes. Viral transmission occurs predominantly through respiratory droplets, but transmission to gametes cannot be ruled out. Since the onset of the pandemic, knowledge about the molecular details of SARS-CoV-2 infection rapidly grew. Coronaviruses are enveloped RNA viruses. For a virus to deliver their genome into the host cell, attachment and entrance into that cell is a crucial step. The coronavirus surface protein spike (S) mediates entry into target cells by binding to a cellular receptor and subsequent fusing of the viral envelope with a host cell membrane. The SARS-CoV-2-S protein (SARS-S) utilizes angiotensin-converting enzyme 2 (ACE2) as a receptor for host cell entry. Host proteases such as transmembrane serine protease 2 (TMPRSS2) are then needed to cleave the viral S protein, allow-ing permanent fusion of the viral and host cell membranes2. Expression of ACE2 and TMPRSS2 has been shown in testicular, uterine and placental cells. Based on available transcriptomic data, co-expression of ACE2 and TMPRSS2 is also seen on oocyte level, but the possible impact on reproduction is unknown. The BSG (basigin or CD147), a receptor on host cells, was also identified as a possible route for viral invasion.

NCT04425317 Infertility COVID IVF Diagnostic Test: Blood sample
MeSH:Infertility
HPO:Infertility

Primary Outcomes

Description: Identification of viral RNA in cumulus-oocyte-complexes, exclusively looking at the material that is considered waste material in a normal oocyte retrieval

Measure: Presence or absence of SARS-CoV-2 in follicular fluid, cumulus cells, immature oocytes and endometrium

Time: 1 day

Secondary Outcomes

Description: Presence of receptors, identified as possible steps in the entry pathway for SARS-CoV-2

Measure: Presence of ACE2, TMPRSS and BSG receptors in cumulus cells, immature oocytes and endometrium

Time: 1 day

5 Assessing the Perception and the Personal Experience of the COVID19 Pandemic Among Infertile Couples Undergoing Assisted Reproductive Treatment (ART)

Non-urgent medical care, such as fertility treatments, has been massively postponed during the past weeks due to the COVID19 pandemic. The lockdown and the closure of IVF centers might cause anxiety and depression among infertile couples, who are already exposed to the distressing experience of infertility and for whom the wait for a baby already appears unending. Few data are available regarding the impact of SARS-CoV-2 on pregnant women and foetus, or on fertility. This study aims to assess the views of infertile couple regarding the potential risks of COVID during their fertility treatment and their personal experience of the COVID pandemic and their expectation for further treatment .

NCT04456010 COVID19 Fertility Issues ART Other: Questionnaire
MeSH:Infertility
HPO:Infertility

Primary Outcomes

Description: Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment, via a survey

Measure: Personal experience of the COVID19 pandemic and the discontinuation of their fertility treatment pandemic and the discontinuation

Time: 1 day

Secondary Outcomes

Description: . Risk assessment by the patient, via a survey, regarding SARS-CoV-2 during a fertility treatment or during pregnancy. Perception of the risks linked to SARS-CoV-2 during their fertility treatment or during a pregnancy

Measure: Risk assessment

Time: 1 day

Description: Patients'expectations regarding the management of an abrupt closure of the fertility center, via a survey

Measure: Patients'expectations regarding the management of an abrupt closure of the fertility center

Time: 1 day


HPO Nodes